Molecular Formula: C18H31N5O9
Molecular Weight: 461.5 g/mol
Peptide purity: Greater than 98%
Other details: No TFA Salt, No Mannitol
Storage: This product must be stored at 4°C. No suitable for freezing.
Livagen, a short peptide that is linked to Epitalon (also known as Epithalon), is well-known for its impact on the liver, GI tract, and immune system. Livagen has a direct impact on DNA & gene expression patterns as a peptide bioregulator. Its alleged anti-aging abilities are assumed to be a consequence of Livagen's capacity to activate immunological and GI tract genes that are normally repressed with aging due to DNA condensation.
According to older individuals' lymphocytes, Livagen stimulates several genes by causing chromatin to decondense (unpack), according to research. This causes the activation of genes that are normally inactive in older individuals, such as ribosomal genes, which are indirectly responsible for strong protein synthesis and increased cell activity.
This evidence implies that Livagen directly affects the DNA of lymphocytes, which are the main immune system cells.
Livagen activates synthetic processes by reactivating ribosomal genes, unpacks chromatin, changes gene expression, and induces decondensation in lymphocytes, according to research examining the endpoints of Livagen, Epitalon, & Vilon administration in older patients.
The chromatin that is silenced as we become older gets reactivated as a result of all of these impacts. Researchers think that this restores lymphocytes to a more "young" condition even though long-term implications have not been investigated.
By now, it ought to be clear that alterations in the sorts of genes that may be accessible and expressed, as well as the way DNA is structured, contribute to many of the impacts of aging. Professor Teimuraz Lezhava, the world's foremost expert on chromatin modifications with age, has documented these changes in studies. His research demonstrates that chromosomal aberration levels rise with aging. Progressive chromatin condensation is one of these anomalies.
There is strong evidence to support the idea that stopping the condensation process might lengthen life. After all, reactivating those genes should decrease the aging process if gene silencing causes it to occur more quickly over time. Livagen, Epitalon, and a few other bioregulatory peptides are already known to influence this process via decondensed DNA, according to Dr. Lezhavas' study. His research suggests that there is solid evidence to support the idea that these peptides may be able to prevent some of the dysfunction that develops with aging, especially for immunological dysregulation and reduced protein synthesis.
Lymphocytes actively contribute to heart health. The dysregulation of lymphocyte chromatin structure is thought to be a pathogenic aspect of hypertrophic cardiomyopathy (HCM) and atherosclerosis, according to research on individuals with the condition.
B cells and T cells are two types of white blood cells found in lymphocytes. B cells create antibodies to fight foreign invaders, while T cells destroy body cells that are either malignant or infested with invaders. Additionally, cytokines, which are chemical messengers that direct immune responses and manage inflammatory reactions in the body, are produced by T cells. In other words, lymphocytes are some of the most crucial immune system cells. Our increased susceptibility to all types of sickness and illness as we age may, at least in part, be attributed to their loss of activity with age. Restoring these cells to a more youthful condition might aid in fighting cancer and infection.
According to many studies, the release of genes through chromatin decondensation in lymphocytes may assist to lessen the long-term effects of several types of heart disease. In people with HCM, changes in lymphocyte gene expression may assist to lessen inflammation and the scarring it causes. Naturally, Livagen performs this same function, thus there has been much study in this area. Livagen could serve as the foundation for cutting-edge preventive measures that lower the total morbidity and death linked to heart disease.
According to recent studies, when activated, the GI tract's mucosal barrier is protected by both my and delta receptors. Overall, Livagen in this situation causes changed levels of mucosal nitric oxide and prostaglandins as well as an increase in vagal nerve signals to the GI tract. This results in significant gastroprotection, which may help treat viral diarrhea as well as ease the signs and long-term effects of inflammatory bowel disease. It should be no surprise that Livagen is being explored as a possible therapy for several GI problems given its capacity to increase activation of these receptors by increasing amounts of enkephalin in the circulation.
Livagen increases the body's supply of natural painkillers by decreasing the activity of enkephalin-degrading enzymes in the blood. The body employs enkephalins, which are brief peptides, to communicate pain. This shows that Livagen could work well for treating pain.
T. Lezhava et al., "Anti-aging peptide bioregulators induce reactivation of chromatin" [PubMed]
N.V. Kost et al., "Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum" [PubMed]
Georgian Med News "Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives" [PubMed]
T. Lezhava et al., "Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals" [Europe PMC]
V.Kh. Khavinson et al., "Effects of Livagen peptide on chromatin activation in lymphocytes from old people" [PubMed]
T. Lezhava "Human chromosome functional characteristics and aging" [PubMed]
N.M. Timofeeva et al., "Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages" [PubMed]
V.K. Khavinson "Tissue-specific effects of peptides" [PubMed]
I. Riadnova et al., "Functional morphology of an organotypic liver culture exposed to the peptide livagen" [PubMed]
T. Jokhadze et al., "Evaluation of genomic parameters in ductal breast cancer patients and the ability of it's correction" [PubMed]
V.K. Khavinson et al., "Effects of short peptides on lymphocyte chromatin in senile subjects" [PubMed]
V.Brodskii et al., "Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen" [PubMed]
B.I. Kuznik et al., "The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology" [PubMed]
V.K. Khavinson et al., "Tissue-specific action of peptides in tissue culture of rats of various ages" [PubMed]
This product is intendend for lab research and development use only. These studies are performed outside of the body. This product is not medicines or drugs and has not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.
All product information provided on this website is for informational and educational purposes only.